Compare · ARGX vs DNA
ARGX vs DNA
Side-by-side comparison of argenx SE (ARGX) and Ginkgo Bioworks Holdings Inc. (DNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and DNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $48.52B, about 92.6x DNA ($523.9M).
- Over the past year, ARGX is up 22.7% and DNA is up 35.7% - DNA leads by 12.9 points.
- DNA has been more active in the news (11 items in the past 4 weeks vs 3 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 17 for DNA).
- Company
- argenx SE
- Ginkgo Bioworks Holdings Inc.
- Price
- $785.11+0.43%
- $9.47+12.07%
- Market cap
- $48.52B
- $523.9M
- 1M return
- +5.49%
- +39.68%
- 1Y return
- +22.73%
- +35.67%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- 2021
- News (4w)
- 3
- 11
- Recent ratings
- 25
- 17
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.
Latest ARGX
- argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
- SEC Form 6-K filed by argenx SE
- argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
- SEC Form 6-K filed by argenx SE
- argenx announces Annual General Meeting of Shareholders on May 6, 2026
- SEC Form 20-F filed by argenx SE
- SEC Form 6-K filed by argenx SE
- argenx upgraded by Deutsche Bank
- SEC Form 6-K filed by argenx SE
- argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
Latest DNA
- Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation
- SEC Form DEFA14A filed by Ginkgo Bioworks Holdings Inc.
- SEC Form DEF 14A filed by Ginkgo Bioworks Holdings Inc.
- SEC Form 4 filed by Coen Steven P.
- SEC Form 4 filed by Coen Steven P.
- SEC Form 4 filed by Canton Barry
- SEC Form 4 filed by Shetty Reshma P.
- SEC Form 4 filed by Shetty Reshma P.
- SEC Form 4 filed by Canton Barry
- SEC Form 4 filed by Kelly Jason R